Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.

ABSTRACT:

Background

B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell immunotherapy has shown promising results in the treatment of relapsed or refractory multiple myeloma (R/RMM). This study presents the updated long-term outcomes from our center.

Methods

Between July 30, 2018, and September 27, 2023, 141 patients with R/RMM who received BCMA CAR-T therapy were enrolled. Patients underwent conditioning chemotherapy with cyclophosphamide and fludarabine, followed by BCMA CAR-T cell infusion at a median dose of 2.36×10⁶ cells/kg. The study evaluated overall response rates, long-term efficacy, safety profiles, and their associations with clinical and disease characteristics.

Results

At a median follow-up of 20.2 months, the safety profi

SUBMITTER: Jin C 

PROVIDER: S-EPMC11956354 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature